France vs Guinea: HIV/AIDS deaths averted by antiretroviral therapy
France
5,635 deaths
in 2022
Guinea
6,473 deaths
in 2024
France rank
32nd
Guinea rank
31st
HIV/AIDS deaths averted by antiretroviral therapy over time
- France
- Guinea
How they compare
Guinea currently reports 6,473 deaths against 5,635 deaths in France, a difference of 838 deaths.
That makes Guinea's figure about 1.1 times France's.
The two have swapped places 2 times across 33 shared years of data; in 1990 it was Guinea ahead.
France ranks 32nd and Guinea ranks 31st of 157 countries.
France has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | France | Guinea | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 869.7 deaths | 0 deaths | 869.7 deaths | France |
| 2000s | 5,347 deaths | 690.29 deaths | 4,657 deaths | France |
| 2010s | 6,037 deaths | 3,770 deaths | 2,268 deaths | France |
| 2020s | 5,744 deaths | 5,367 deaths | 376.84 deaths | France |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, France or Guinea?
- Guinea, at 6,473 deaths against 5,635 deaths in France as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between France and Guinea?
- 838 deaths, with Guinea ahead.
- How many years of comparable data are there for France and Guinea?
- 33 years are reported by both, from 1990 to 2022.
- How do France and Guinea rank globally for hiv/aids deaths averted by antiretroviral therapy?
- France ranks 32nd and Guinea ranks 31st of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.